GT
AGTC

Glenmede Trust’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Glenmede Trust’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed – – 2859
2015
Q2 		$0 Hold
1
– – ﹤0.01% 2804
2015
Q1 		$0 Buy
+1
New +$22 ﹤0.01% 2571

Other funds holding AGTC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust's AGTC Position: Q3 2015 in Review

Glenmede Trust sold out of Applied Genetic Technologies Corporation (AGTC) in Q3 2015, closing a stake of 1 share.

Glenmede Trust first reported a position in AGTC in Q1 2015 and held it in 2 quarters. The position peaked at $0 in Q2 2015. 60 funds tracked by Wall St. Rank hold AGTC as of Q3 2015.

  • Glenmede Trust reported no remaining Applied Genetic Technologies Corporation position as of Q3 2015 after selling out during the quarter.
  • Glenmede Trust sold 1 Applied Genetic Technologies Corporation share in Q3 2015.
  • Glenmede Trust first reported a position in Applied Genetic Technologies Corporation in Q1 2015 and held it in 2 quarters.
  • Glenmede Trust's Applied Genetic Technologies Corporation position peaked at $0 in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q3 2015.

Based on Glenmede Trust's 13F filing for Q3 2015, filed 12 Nov 2015.